The addition of agonistic LTβR antibodies to anti-VEGF plus anti-PDL1 therapy, thus fully activating the LTβR signaling cues, further increased HEV numbers and maturation in breast and pancreatic cancer and sensitized glioblastoma to the therapy. This evidence concerns the gene LTBR and familial pancreatic carcinoma.